View in EDS

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Saved in:
Bibliographic Details
Title: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Authors: Hisato Kawakami, Jeeyun Lee, Hyun-Cheol Chung, Kaku Saito, Yung-Jue Bang, Kensei Yamaguchi, Satoru Iwasa, Daisuke Sakai, Akihito Kojima, Yoshinori Kawaguchi, DESTINY-Gastric Investigators, Min-Hee Ryu, Naotoshi Sugimoto, Takahiro Kamio, Kohei Shitara, Masahiro Sugihara, Hiroshi Yabusaki
Contributors: Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kensei Yamaguchi, DESTINY-Gastric01 Investigators, Chung, Hyun Cheol
Source: New England Journal of Medicine. 382:2419-2430
Publisher Information: Massachusetts Medical Society, 2020.
Publication Year: 2020
Subject Terms: Lung Diseases, Adult, Male, 0301 basic medicine, Immunoconjugates, Camptothecin / analogs & derivatives, Esophageal Neoplasms, Paclitaxel, Receptor, ErbB-2, Humanized / adverse effects, Camptothecin / therapeutic use, Antineoplastic Agents, Stomach Neoplasms / drug therapy, Antineoplastic Agents / therapeutic use, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Irinotecan, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, Stomach Neoplasms, Monoclonal, 80 and over, Humans, Irinotecan / therapeutic use, Humanized / therapeutic use, Aged, Aged, 80 and over, Esophageal Neoplasms / drug therapy, Interstitial / chemically induced, Bone Marrow / drug effects, Antineoplastic Agents / adverse effects, Immunoconjugates / adverse effects, Middle Aged, Survival Analysis, Immunoconjugates / therapeutic use, 3. Good health, Adenocarcinoma / drug therapy, Camptothecin / adverse effects, ErbB-2 / analysis, Camptothecin, Female, Paclitaxel / therapeutic use, Lung Diseases, Interstitial, Receptor
Description: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric cancer.In an open-label, randomized, phase 2 trial, we evaluated trastuzumab deruxtecan as compared with chemotherapy in patients with HER2-positive advanced gastric cancer. Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab, were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan (6.4 mg per kilogram of body weight every 3 weeks) or physician's choice of chemotherapy. The primary end point was the objective response, according to independent central review. Secondary end points included overall survival, response duration, progression-free survival, confirmed response (response persisting ≥4 weeks), and safety.Of 187 treated patients, 125 received trastuzumab deruxtecan and 62 chemotherapy (55 received irinotecan and 7 paclitaxel). An objective response was reported in 51% of the patients in the trastuzumab deruxtecan group, as compared with 14% of those in the physician's choice group (P
Document Type: Article
Language: English
ISSN: 1533-4406
0028-4793
DOI: 10.1056/nejmoa2004413
Access URL: https://pubmed.ncbi.nlm.nih.gov/32469182
https://s-space.snu.ac.kr/handle/10371/173254
https://www.ncbi.nlm.nih.gov/pubmed/32469182
https://pubmed.ncbi.nlm.nih.gov/32469182/
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2004413
https://www.nejm.org/doi/full/10.1056/NEJMoa2004413
https://www.scilit.net/article/0f065665446dafb82b21c79c6d3f6e1b
Rights: CC BY NC ND
URL: http://www.nejmgroup.org/legal/terms-of-use.htm
Accession Number: edsair.doi.dedup.....67a4ef70fcc265e12aac9a6282d216c1
Database: OpenAIRE
Description
Abstract:Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric cancer.In an open-label, randomized, phase 2 trial, we evaluated trastuzumab deruxtecan as compared with chemotherapy in patients with HER2-positive advanced gastric cancer. Patients with centrally confirmed HER2-positive gastric or gastroesophageal junction adenocarcinoma that had progressed while they were receiving at least two previous therapies, including trastuzumab, were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan (6.4 mg per kilogram of body weight every 3 weeks) or physician's choice of chemotherapy. The primary end point was the objective response, according to independent central review. Secondary end points included overall survival, response duration, progression-free survival, confirmed response (response persisting ≥4 weeks), and safety.Of 187 treated patients, 125 received trastuzumab deruxtecan and 62 chemotherapy (55 received irinotecan and 7 paclitaxel). An objective response was reported in 51% of the patients in the trastuzumab deruxtecan group, as compared with 14% of those in the physician's choice group (P
ISSN:15334406
00284793
DOI:10.1056/nejmoa2004413